Your browser doesn't support javascript.
loading
The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS).
Dumas, Elise; Laot, Lucie; Coussy, Florence; Grandal Rejo, Beatriz; Daoud, Eric; Laas, Enora; Kassara, Amyn; Majdling, Alena; Kabirian, Rayan; Jochum, Floriane; Gougis, Paul; Michel, Sophie; Houzard, Sophie; Le Bihan-Benjamin, Christine; Bousquet, Philippe-Jean; Hotton, Judicaël; Azencott, Chloé-Agathe; Reyal, Fabien; Hamy, Anne-Sophie.
Affiliation
  • Dumas E; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France.
  • Laot L; INSERM, U900, 75005 Paris, France.
  • Coussy F; MINES ParisTech, CBIO-Centre for Computational Biology, PSL Research University, 75006 Paris, France.
  • Grandal Rejo B; Department of Surgical Oncology, Institut Curie, University of Paris, 75005 Paris, France.
  • Daoud E; Department of Medical Oncology, Institut Curie, University of Paris, 75005 Paris, France.
  • Laas E; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France.
  • Kassara A; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France.
  • Majdling A; INRIA, DI/ENS, PSL Research University, 75006 Paris, France.
  • Kabirian R; Department of Surgical Oncology, Institut Curie, University of Paris, 75005 Paris, France.
  • Jochum F; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France.
  • Gougis P; Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France.
  • Michel S; Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France.
  • Houzard S; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France.
  • Le Bihan-Benjamin C; Department of Gynecology, Strasbourg University Hospital, 67091 Strasbourg, France.
  • Bousquet PJ; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France.
  • Hotton J; Department of Surgical Oncology, Institut Curie, University of Paris, 75005 Paris, France.
  • Azencott CA; Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 92100 Boulogne-Billancourt, France.
  • Reyal F; Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 92100 Boulogne-Billancourt, France.
  • Hamy AS; Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 92100 Boulogne-Billancourt, France.
Cancers (Basel) ; 14(11)2022 May 27.
Article in En | MEDLINE | ID: mdl-35681651
ABSTRACT

BACKGROUND:

Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death in women. The French National Cancer Institute has created a national cancer cohort to promote cancer research and improve our understanding of cancer using the National Health Data System (SNDS) and amalgamating all cancer sites. So far, no detailed separate data are available for early BC.

OBJECTIVES:

To describe the creation of the French Early Breast Cancer Cohort (FRESH).

METHODS:

All French women aged 18 years or over, with early-stage BC newly diagnosed between 1 January 2011 and 31 December 2017, treated by surgery, and registered in the general health insurance coverage plan were included in the cohort. Patients with suspected locoregional or distant metastases at diagnosis were excluded. BC treatments (surgery, chemotherapy, targeted therapy, radiotherapy, and endocrine therapy), and diagnostic procedures (biopsy, cytology, and imaging) were extracted from hospital discharge reports, outpatient care notes, or pharmacy drug delivery data. The BC subtype was inferred from the treatments received.

RESULTS:

We included 235,368 patients with early BC in the cohort (median age 60 years). The BC subtype distribution was as follows luminal (80.2%), triple-negative (TNBC, 9.5%); HER2+ (10.3%), or unidentifiable (n = 44,388, 18.9% of the cohort). Most patients underwent radiotherapy (n = 200,685, 85.3%) and endocrine therapy (n = 165,655, 70.4%), and 38.3% (n = 90,252) received chemotherapy. Treatments and care pathways are described.

CONCLUSIONS:

The FRESH Cohort is an unprecedented population-based resource facilitating future large-scale real-life studies aiming to improve care pathways and quality of care for BC patients.
Key words

Full text: 1 Database: MEDLINE Type of study: Guideline Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Type of study: Guideline Language: En Year: 2022 Type: Article